May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
24-Hour Intraocular Pressure and Blood Pressure Control With Latanoprost/Timolol Maleate Fixed Combination QPM and Timolol Maleate BID in Primary Open Angle Glaucoma Patients
Author Affiliations & Notes
  • S. Tsironi
    Department of Ophthalmology, Papanikolaou Hospital, Thessaloniki, Greece
  • A. G. P. Konstas
    1st Department of Ophthalmology,
    Aristotle University of Thessaloniki, Thessaloniki, Greece
  • M. I. Pikilidou
    1st Department of Medicine,
    Aristotle University of Thessaloniki, Thessaloniki, Greece
  • D. Mikropoulos
    1st Department of Ophthalmology,
    Aristotle University of Thessaloniki, Thessaloniki, Greece
  • V. P. Kozobolis
    Department of Ophthalmology, Democritus University of Thrace, Alexandroupolis, Greece
  • A. N. Lasarides
    1st Department of Medicine,
    Aristotle University of Thessaloniki, Thessaloniki, Greece
  • W. C. Stewart
    Pharmaceutical Research Network, LLC, Charleston, South Carolina
  • Footnotes
    Commercial Relationships S. Tsironi, None; A.G.P. Konstas, Pfizer, F; M.I. Pikilidou, None; D. Mikropoulos, None; V.P. Kozobolis, None; A.N. Lasarides, None; W.C. Stewart, None.
  • Footnotes
    Support This study was supported in part by an unrestricted grant from Pfizer, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5565. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Tsironi, A. G. P. Konstas, M. I. Pikilidou, D. Mikropoulos, V. P. Kozobolis, A. N. Lasarides, W. C. Stewart; 24-Hour Intraocular Pressure and Blood Pressure Control With Latanoprost/Timolol Maleate Fixed Combination QPM and Timolol Maleate BID in Primary Open Angle Glaucoma Patients. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5565.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate intraocular pressure (IOP) and blood pressure (BP) control in primary open-angle glaucoma patients (POAG) before and after therapy with timolol bid and latanoprost/timolol fixed combination (LTFC) qpm.

Methods:: Randomized, observer-masked, placebo-controlled, crossover study that investigating IOP and BP of POAG patients without systemic hypertension. Following a 6-week washout period patients underwent baseline assessment of IOP and BP. Patients were then randomized to either LTFC qpm (8 PM) and placebo qam (8 AM) or timolol bid (8 AM and 8 PM). After 2 months on the first treatment patients were crossed over to the opposite treatment for an additional 2 months. Patients underwent 24-hour IOP curves by Goldmann applanation tonometry at 6 AM, 10 AM, 2 PM, 6 PM, 10 PM and 2 AM. BP was evaluated every 30 minutes during waking hours and every hour while asleep (Spacelabs 90217 ambulatory BP monitor).

Results:: 28 POAG patients were included with an average 24-hour baseline IOP of 26.3±2.4 mm Hg and an average baseline mean BP of 90.9±7.6 mm Hg. Following 2 months of treatment no statistical difference existed between untreated and treated values for all BP parameters during the daytime or nighttime periods and no differences were detected between the 2 drugs for all BP parameters evaluated. LTFC did show superior IOP reduction for mean 24-hour IOP and at all time points compared with timolol (mean 24-hour IOP difference -2.6 mm Hg, P<0.0001).

Conclusions:: This 24-hour study could not detect a clinically important, or statistically significant, impact of timolol or LTFC upon the BP parameters of POAG patients without systemic hypertension. LTFC had significantly better 24-hour IOP lowering efficacy than timolol.

Clinical Trial:: www.clinicaltrials.gov NCT00330577

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×